Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 27, 2025, to November 11, 2025, seeking damages for misleading statements regarding the company's financial health and operations [1]. Group 1: Lawsuit Details - The class action was filed in the United States District Court for the Central District of California, seeking to recover damages for all persons and entities that purchased Beyond Meat securities during the specified Class Period [1]. - Investors have until March 24, 2026, to request appointment as Lead Plaintiff for the class [1]. Group 2: Company Background - Beyond Meat operates in the food industry, focusing on developing, manufacturing, marketing, and selling plant-based meat products under the "Beyond" brand in the U.S. and internationally [1]. - The company has been facing challenges such as shrinking demand, increasing debt, and losses, with a primary goal of achieving positive EBITDA by the end of 2026 [1]. Group 3: Allegations and Financial Impact - The complaint alleges that Defendants made materially false and misleading statements about the company's business and operations, failing to disclose significant asset impairment charges that were likely to occur [1]. - On October 24, 2025, Beyond Meat reported an expected non-cash impairment charge for Q3 2025, leading to a stock price drop of 23.06% [1]. - Subsequent announcements regarding delays in financial reporting and actual impairment charges resulted in further declines in stock price, with a reported loss from operations of $112.3 million for Q3 2025, including $77.4 million in non-cash impairment charges [1].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who acquired Inovio securities during this time [1] Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [1] - The company's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [1] Allegations and Misstatements - Defendants allegedly made materially false and misleading statements regarding Inovio's business and prospects, including: - Deficiencies in the manufacturing of the CELLECTRA device [1] - Unlikelihood of submitting the INO-3107 Biologics License Application (BLA) to the FDA by the second half of 2024 [1] - Insufficient information to justify eligibility for FDA accelerated approval or priority review [1] - Overstated regulatory and commercial prospects for INO-3107 [1] Stock Price Impact - Following the revelation of a manufacturing issue on August 8, 2024, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [1] - On December 29, 2025, after the FDA accepted the INO-3107 BLA on a standard review timeline, the stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 [1]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Ramaco Resources, Inc. (NASDAQ: METC) about a class action lawsuit related to misleading statements made by the company during a specified class period [1] Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from July 31, 2025, to October 23, 2025 [1] - Allegations include that the defendants did not commence significant mining activity at the Brook Mine after groundbreaking, and no active work was taking place at the site [1] - The company is accused of overstating development progress at the Brook Mine, leading to materially misleading statements about its business and operations [1] Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by March 31, 2026 [1] - Registration will provide access to portfolio monitoring software for status updates throughout the case lifecycle [1] Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [1] - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock [1]

Core Viewpoint - Beyond Meat, Inc. (BYND) is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding the valuation of its long-lived assets and its ability to file periodic reports with the SEC [1] Group 1: Class Action Details - The class period for the lawsuit is from February 27, 2025, to November 11, 2025 [1] - Allegations include that Beyond Meat's long-lived assets had a book value exceeding their fair value, likely necessitating a material, non-cash impairment charge [1] - The lawsuit claims that these issues could impair Beyond Meat's ability to file timely reports with the SEC, rendering public statements by the defendants materially false and misleading [1] Group 2: Next Steps for Shareholders - Shareholders who purchased BYND shares during the specified class period are encouraged to register for the class action by March 24, 2026 [1] - Registration allows shareholders to be enrolled in a portfolio monitoring software for updates throughout the case lifecycle [1] - Participation in the case incurs no cost or obligation for shareholders [1]

Core Viewpoint - The Gross Law Firm has announced a lead plaintiff deadline of April 3, 2026, for shareholders of Plug Power Inc. (NASDAQ: PLUG) who purchased shares during the specified class period, indicating potential legal action due to alleged misleading statements by the company [1]. Group 1: Legal Action Details - The class period for the lawsuit is defined as January 17, 2025, to November 13, 2025 [1]. - Allegations include that Plug Power's management overstated the likelihood of receiving funds from the U.S. Department of Energy's Loan Program and misrepresented the company's ability to construct necessary hydrogen production facilities [1]. - The lawsuit claims that as a result of these misrepresentations, Plug Power may need to shift focus to less ambitious projects, which could impact its commercial prospects [1]. Group 2: Shareholder Participation - Shareholders are encouraged to register for the class action to potentially become lead plaintiffs, although this appointment is not necessary to participate in any recovery [1]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [1]. - The Gross Law Firm emphasizes that there is no cost or obligation for shareholders to participate in the case [1].

Core Viewpoint - Klarna Group plc is facing a lawsuit for securities law violations related to its initial public offering (IPO) on September 10, 2025, with allegations of materially false and misleading statements regarding loss reserves [1][1][1] Summary by Relevant Sections Allegations - The lawsuit claims that Klarna's defendants materially understated the risk of increased loss reserves shortly after the IPO, which they either knew or should have known due to the risk profile of customers using Klarna's buy now, pay later loans [1][1] - It is alleged that the public statements made by the defendants were materially false and misleading at all relevant times and were negligently prepared [1][1] Class Period and Deadlines - The class period for the lawsuit includes individuals who purchased Klarna securities pursuant to the registration statement and related prospectus issued during the IPO [1][1] - Shareholders are encouraged to register for the class action by February 20, 2026, to participate in potential recovery [1][1] Next Steps for Shareholders - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [1][1] - There is no cost or obligation for shareholders to participate in the case [1][1]

Contact The Gross Law Firm by March 13, 2026 Deadline to Join Class Action Against CoreWeave, Inc.(CRWV) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CoreWeave, Inc. (NASDAQ: CRWV).Shareholders who purchased shares of CRWV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.C ...

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against Picard Medical, Inc. (NYSE: PMI) for allegedly misleading shareholders during a specified class period, with a lead plaintiff deadline set for April 3, 2026 [1]. Group 1: Allegations - The lawsuit claims that during the class period from September 2, 2025, to October 31, 2025, Picard Medical, Inc. made materially false and misleading statements [1]. - Allegations include involvement in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals [1]. - It is also alleged that insiders used offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign [1]. - The company's public statements and risk disclosures reportedly omitted critical information regarding false rumors and artificial trading activity affecting stock prices [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased PMI shares during the specified timeframe are encouraged to register for the class action to potentially become lead plaintiffs [1]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [1]. - Participation in the case incurs no cost or obligation for the shareholders [1].

KLAR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Klarna Group plc (KLAR) Investors of Securities Class Action Deadline on February 20, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In Klarna To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [Klarna] pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registr ...

Core Insights - Klarna Group plc (NYSE:KLAR) is recognized as one of the 12 best digital currency and payments stocks to invest in currently [1] - The company has launched instant peer-to-peer payments across 13 European nations, enhancing its in-app payment capabilities [2] - Klarna reported a 26% increase in third-quarter revenue, reaching $1 billion, despite a net loss of $95 million due to accounting changes following its public listing [4] Financial Performance - Klarna's revenue for the current quarter is anticipated to be $1.07 billion, slightly above the previous quarter's forecast of $1.06 billion [4] - The company experienced a significant revenue growth in U.S. markets, contributing to its overall performance [4] - Keefe Bruyette maintained an Outperform rating for Klarna but adjusted its price target from $52 to $45 [3] Business Operations - Klarna operates as a global digital bank, providing flexible payment options through an AI-powered payments and commerce network [5] - The introduction of peer-to-peer payments allows users to send money directly to friends and family via the Klarna app, expanding its service offerings beyond in-store purchases [2][8]